

# Effect of the recall software Impfdoc on vaccination rates among paediatricians

<b>Submission date</b> 16/04/2008	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 16/05/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 02/10/2008	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Rüdiger von Kries

**Contact details**  
Institut für Soziale Pädiatrie und Jugendmedizin  
Heiglhofstr. 63  
Munich  
Germany  
81377

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**

**Acronym**  
EERSV

**Study objectives**

Children who are treated by paediatricians who use the recall software Impfdoc have higher vaccination rates than those treated by paediatricians not using the software.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics Board of the Medical faculty, University of Munich. Approved on 04/04/2008 (Project no. 035-08)

**Study design**

Cluster-randomised controlled trial.

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Vaccination rates

**Interventions**

Paediatricians are offered the software Impfdoc and an instruction for the software free of charge. One group receives the software earlier (intervention group) and one group later (control group). The delay in the distribution of the software depends on the organisation of the instructions. The control group is expected to receive the software 3-6 months later.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Proportion of children who received full immunisation until the age of 12 months according to the recommendations of the German standing committee on vaccinations (Ständige Impfkommision STIKO).

**Key secondary outcome(s)**

Proportion of children who have received their second dose of measles vaccination, assessed at the age of 2 years.

**Completion date**

31/12/2010

**Eligibility****Key inclusion criteria**

Paediatricians in Bavaria, Germany, and children treated by these paediatricians.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Sex**

All

**Key exclusion criteria**

Children switching paediatricians (only if paediatricians are not in same study group) within the study period.

**Date of first enrolment**

01/08/2008

**Date of final enrolment**

31/12/2010

## **Locations**

**Countries of recruitment**

Germany

**Study participating centre**

Institut für Soziale Pädiatrie und Jugendmedizin

Munich

Germany

81377

## **Sponsor information**

**Organisation**

Individual sponsor (Germany)

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Institute for Medical Information (Institut für medizinische Information) (Germany)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration